<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717532</url>
  </required_header>
  <id_info>
    <org_study_id>18-01123</org_study_id>
    <nct_id>NCT03717532</nct_id>
  </id_info>
  <brief_title>Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome</brief_title>
  <official_title>Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of blood restriction therapy by
      comparing increase in muscle mass and strength in patients that receive blood restriction
      therapy to patients who receive a placebo.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate/low enrollment
  </why_stopped>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in Muscle Mass Measured by Biodex</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Biodex dynamometer is used under standard of care to measure the extensor strength of both legs and have bilateral thigh circumference measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease in Pain measured by Visual Analog Scale (VAS)</measure>
    <time_frame>6 Weeks</time_frame>
    <description>100-mm horizontal line anchored at one end with the words &quot;no pain&quot; and at the other end with the words &quot;worst pain imaginable.&quot;</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Patellofemoral Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients with Patellopain syndrome with Cuff</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Patellopain syndrome with Placebo Cuff</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.</description>
    <arm_group_label>Patients with Patellopain syndrome with Placebo Cuff</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Personalized Tourniquet System for Blood Flow Restriction</intervention_name>
    <description>Patients will be receiving blood flow restriction therapy with a pressure cuff</description>
    <arm_group_label>Patients with Patellopain syndrome with Cuff</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class I-II

          -  Diagnosed with patellofemoral pain syndrome

        Exclusion Criteria:

          -  Patients with confirmed radiographic evidence explaining knee pain

          -  Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia,
             etc.)

          -  Younger than 18 years of age or older than 65

          -  Any patient considered a vulnerable subject

          -  Patients with impaired circulation, peripheral vascular compromise, Previous
             revascularization of the extremity, or severe hypertension

          -  Patients with Sickle cell anemia or venous thromboembolism

          -  Patients with Sickle cell anemia or venous thromboembolism

          -  Patients with cancer or Lymphectomies

          -  Patients with increased intracranial pressure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillen Gonzalez-Lomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Patellofemoral Pain Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

